This area is reserved for registered users. Please register or login.

Tremfya ▼ Receives Approval for Treatment of Moderate to Severe Plaque Psoriasis

Janssen is pleased to announce that Tremfya (guselkumab) is now available in Ireland for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.1 Guselkumab, a human IgG1l monoclonal antibody, is the first biologic that selectively blocks interleukin (IL)-23, a key driver of the immune inflammatory response in psoriasis.   IL-23 affects the differentiation, expansion, and survival of T cell and innate immune cell subsets, which represent sources of effector cytokines, including IL-17A, IL-17F and IL-22 that drive inflammatory disease. Guselkumab selectively binds to IL-23 and blocks its interaction with cell surface receptors, disrupting…